SCHEMBL14928375

SCHEMBL14928375

CCc1cc(C)c(N)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
CYP1A2 P05177 1/20 0.50
ALOX15 P16050 1/20 0.50
CASP7 P55210 1/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CD44 P16070 1/20 0.48
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
CYP3A4 P08684 4/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 1/20 0.42
GAA P10253 2/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10341258 0.84 ALDH1A1 (0.64) ALDH1A1CYP1A2ALOX15CASP7HIF1A
SCHEMBL7470752 0.84 CD44 (0.48) ALDH1A1ALOX15CD44GRIN2DGRIN3B
SCHEMBL10948580 0.82 GAA (0.57) ALDH1A1ALOX15HSD17B10CD44GRIN2D
SCHEMBL14191477 0.81 GRIN2D (0.48) ALDH1A1CYP1A2ALOX15CASP7HIF1A
SCHEMBL31123471 0.79 ALDH1A1 (0.70) ALDH1A1CYP1A2ALOX15CASP7HIF1A
SCHEMBL28656722 0.79 ALDH1A1 (0.70) ALDH1A1CYP1A2ALOX15CASP7HIF1A
SCHEMBL12811480 0.79 GRIN2D (0.47) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14928646 0.78 GRIN2D (0.42) ALDH1A1CYP1A2ALOX15CASP7HIF1A
SCHEMBL1426074 0.77 GAA (0.50) ALDH1A1CYP1A2ALOX15HSD17B10CD44
SCHEMBL6944526 0.76 CD44 (0.62) ALDH1A1CYP1A2ALOX15CASP7HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 WO disclosed
US-20140163026-A1 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER AFRAXIS HOLDINGS, INC. (US) 2014-06-12 US disclosed
US-20130116263-A1 PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AFRAXIS, INC. (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116263-A1 PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS PAK2, PAK3, PAK1 ALDH1A1 2927/4885CYP1A2 4851/4885ALOX15 4061/4885
US-20140163026-A1 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER PAK2, PAK1, PAK6 ALDH1A1 1936/4885CYP1A2 4050/4885ALOX15 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.